Enzyme-metabolic combination cancer therapy
By combining arginase, arginine succinate synthase, asparaginase, and insulin, along with glucose depletion and ketone body compounds, a rapid and selective killing effect on cancer cells was achieved, solving the problem of coexistence of cancer cells and healthy cells in existing treatments.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- KYON BIOTECH AG
- Filing Date
- 2024-10-25
- Publication Date
- 2026-06-05
AI Technical Summary
Existing arginine-depleting enzyme therapy for cancer cannot achieve rapid and selective killing of cancer cells, and the reduction in free arginine levels is insufficient, allowing both cancer cells and healthy cells to survive for extended periods.
By combining arginase, arginine succinate synthase, asparaginase and insulin, the concentrations of arginine, citrulline, asparagine and glutamine are systematically reduced under glucose depletion conditions, and ketone body compounds are used to replenish energy, thereby achieving rapid killing of cancer cells.
Under glucose depletion conditions, arginine and glutamine are depleted through enzymatic means, which rapidly kills cancer cells, while healthy cells recover and proliferate after only a brief period of damage.